玫瑰红孟加拉光动力抗菌疗法:中期临床与手术结局综述
回顾性队列研究纳入2016年1月至2020年7月在Bascom Palmer眼科研究所接受玫瑰红孟加拉光动力抗菌疗法(RB-PDAT)治疗的31眼/30例难治性感染性角膜炎患者,平均随访28.0±14.4个月,77.4%临床治愈,2年移植存活概率78.7%。
要点
- RB-PDAT后77.4%患者临床治愈,平均治愈时间2.72±1.85个月。
- 22.5%需治疗性穿透性角膜移植,54.8%后续需光学性穿透性角膜移植。
- 2年总体移植存活概率78.7%,移植失败率21.3%。
核心结论
- RB-PDAT是感染性角膜炎的潜在辅助疗法,可能减少治疗性穿透性角膜移植的需求。
- RB-PDAT后接受角膜移植的患者术后1年移植存活概率可能更高。
研究设计与样本
- 回顾性队列研究,纳入2016年1月至2020年7月在Bascom Palmer眼科研究所接受RB-PDAT的31眼/30例连续难治性感染性角膜炎患者。
- 收集人口学、危险因素、微生物诊断、最佳矫正视力、RB-PDAT后临床结局及角膜移植后并发症率,移植存活用Kaplan-Meier曲线及log-rank检验评估。
主要发现
- 平均年龄53±18.0岁,70%为女性,53.3%自认非西班牙裔白人,43.3%为西班牙裔,平均随访28.0±14.4个月。
- 危险因素包括隐形眼镜使用(80.6%)、感染性角膜炎史(19.3%)和眼表疾病(16.1%)。
- 培养阳性为棘阿米巴(51.6%)、镰刀菌(12.9%)和假单胞菌(6.5%);棘阿米巴感染者中22.5%同时接受米替福新治疗。
- RB-PDAT后平均2.72±1.85个月时77.4%患者临床治愈,22.5%需治疗性穿透性角膜移植,54.8%后续需光学性穿透性角膜移植。
- 2年时总体移植存活概率78.7%,移植失败率21.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the intermediate-term clinical outcomes of Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) for infectious keratitis; secondarily, to evaluate the surgical outcomes of individuals who underwent optical keratoplasty after RB-PDAT. DESIGN: Retrospective cohort study. METHOD: A retrospective chart review was performed of 31 eyes from 30 consecutive individuals with infectious keratitis refractory to standard medical therapy who underwent RB-PDAT at the Bascom Palmer Eye Institute between January 2016 and July 2020. Data collected included demographics, risk factors for infectious keratitis, microbiological diagnosis, best spectacle-corrected visual acuity (BCVA), clinical outcomes after RB-PDAT, and complication rates post-keratoplasty. RB-PDAT was performed as described in previous studies. Graft survival was evaluated using Kaplan-Meier curves with log-ranks in individuals who underwent keratoplasty after RB-PDAT. RESULTS: The mean age of the study population was 53 ± 18.0 years. In all, 70% were female; 53.3% self-identified as non-Hispanic White and 43.3% as Hispanic. Mean follow-up time was 28.0 ± 14.4 months. Risk factors included contact lens use (80.6%), history of infectious keratitis (19.3%), and ocular surface disease (16.1%). Cultures were positive for Acanthamoeba (51.6%), Fusarium (12.9%), and Pseudomonas (6.5%). Of the individuals with Acanthamoeba infection, 22.5% were treated with concomitant Miltefosine. Clinical resolution was achieved in 77.4% of patients on average 2.72 ± 1.85 months after RB-PDAT, with 22.5% requiring therapeutic penetrating keratoplasties and 54.8% subsequently requiring optical penetrating keratoplasties. At 2 years, the overall probability of graft survival was 78.7%, and the graft failure rate was 21.3%. CONCLUSION: RB-PDAT is a potential adjunct therapy for infectious keratitis that may reduce the need for a therapeutic penetrating keratoplasty. Patients who undergo keratoplasty after RB-PDAT may have a higher probability of graft survival at 1 year postoperatively.
引用
- Sepulveda-Beltran PA, Levine H, Altamirano DS, et al. Rose Bengal Photodynamic Antimicrobial Therapy: A Review of the Intermediate-Term Clinical and Surgical Outcomes. Am J Ophthalmol. 2022. PMID: 35952754. doi:10.1016/j.ajo.2022.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。